Вакцина для профилактики оспы (Вакцина против натуральной оспы и других ортопоксвирусных инфекций на основе вируса осповакцины живая культуральная, ВакцинаVAC∆6)
№ VAC∆6-01/18 Открытое контролируемое исследование безопасности и переносимости вакцины против натуральной оспы и других ортопоксвирусных инфекций на основе вируса осповакцины живой культуральной (Вакцина VAC∆6) на добровольцах в возрасте 18-40 лет
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/86/2019-02-27/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного.
- В исследовании участвуют здоровые добровольцы.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–40 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 60 чел. в стране «Россия».
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (12.2020) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 31
Критерии включения
- Consent to participate in the study after written informing.
- Healthy volunteers (men and women) aged 18 to 40:
- absence of somatic or infectious diseases during the last 6 months;
- body weight of volunteers should not go beyond 20% of the ideal body weight for a given sex, age, and height;
- absence during the last 6 months of antiviral therapy, the use of steroids (except for the local use of steroids in the form of ointments, eye drops, sprays or inhalations), immunomodulatory dugs;
- persons not infected with HIV, viral hepatitis B and C, lues;
- clinical and laboratory parameters within the range as follows: leukocytes: from 4,000 to 10,000 cells/mm³; platelets: 180,000 to 320,000 per mm³.
Критерии невключения
- Hypersensitivity to any component of the product, allergy to vaccine components.
- Pregnancy or breastfeeding.
- The military.
- Persons in custody in detention facilities and those serving sentences in correctional facilities.
- Children under the age of 18.
- Acute infectious or non-infectious diseases, exacerbation of chronic diseases less than 4 weeks prior to the study.
- Tuberculosis (pulmonary and extrapulmonary).
- Skin diseases: a) common dermatoses (pemphigus, psoriasis, eczema, atopic dermatitis), including those in the past; other acute and chronic diseases or impaired skin cover (burns, impetigo, herpes, herpes zoster chicken pox, pustular diseases).
- Immunosuppressive conditions: congenital or acquired immunodeficiency syndrome (including HIV infection), leukemia, malignant neoplasms, organ transplantation, cellular and humoral immunodeficiencies.
- Immunosuppressive therapy: treatment with antimetabolites, high doses of corticosteroids for 14 days or more, radio and x-ray therapy, etc.
- Cardiovascular diseases: decompensated heart defects, subacute bacterial endocarditis, myocarditis, pericarditis, hypertension of II-III degrees, angina pectoris, myocardial infarction; other forms of pathology: hypertension of the 1st degree, well-controlled heart defects, angina pectoris (mild forms).
- Diseases of the kidneys and urinary tract: diffuse glomerulonephritis, congenital nephropathy, chronic renal failure, pyelonephritis, toxic nephropathy (transient).
- Diseases of the digestive system: cirrhosis of the liver, chronic hepatitis, hepatocerebral dystrophy, acute and chronic pancreatitis, diseases of the biliary tract, gastric ulcer and duodenal ulcer, ulcerative colitis.
- Diseases of the endocrine system: diabetes mellitus, severe forms of thyrotoxicosis and adrenal insufficiency or dysfunction, thymomegaly, congenital enzymopathy.
- Systemic connective tissue diseases: systemic lupus erythematosus, discoid lupus, rheumatism, rheumatoid arthritis, systemic vasculitis, systemic scleroderma.
- Blood diseases: leukemia, Hodgkin's disease, aplastic anemia, hemophilia, Werlhof's disease; hemolytic conditions; deficiency anemia.
- Allergic diseases: bronchial asthma; asthmatic bronchitis, asthmatic syndrome (associated with a respiratory infection); severe anaphylactic reactions (shock, angioedema of the larynx, etc.) to a variety of food, drug and other allergens; allergic reactions to individual allergens (various rashes, clinical disorders, etc.).
- Diseases of the ear, throat, nose: chronic tonsillitis and adenoiditis requiring surgical treatment; chronic otitis.
- Surgery within the previous 2 months.
- Simultaneous participation in other clinical trials.
- Persons with alcohol, drug or drug addiction.
- The presence of mental illness and neurasthenia.
- Previous treatment with human immunoglobulin preparations, if less than 6 months have passed since the treatment.
- Failure to meet inclusion criteria.
- Vaccination with any vaccine less than 2 months prior to study entry.
- Premenopausal women (last menstrual period ≤ 1 year prior to signing the informed consent) who are not surgically sterile.
- Women who have reproductive potential or do not use or plan to use approved birth control products throughout the study nor they agree to a urine pregnancy test while participating in the study. Acceptable birth control methods include extrauterine devices, oral, implanted, or injectable contraceptives.
- Nervous and mental diseases: injuries of the central nervous system (CNS) with residual effects, encephalitis and encephalomyelitis (including post-vaccination), meningitis, polyradiculoneuritis (including those in the past), epilepsy, decompensates or subcompensated hydrocephalus, demyelinating and degenerative lesions of the nervous system (muscle degeneration, etc.), stroke; compensated hydrocephalus, Down's disease, Little's disease, CNS trauma without residual effects, history of febrile convulsions, mental illness.
- Positive analysis for HIV, viral hepatitis B and C, lues.
- Concomitant diseases that, in the opinion of the investigator, may interfere with the evaluation of the objectives of the study.
- Serious post-vaccination reactions/complications associated with any previous vaccination.
Источник: ClinicalTrials.gov, NCT05762523 · запись обновлена в реестре 9 марта 2023.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 5
- Changes in the percentage of vaccinees with a titer of virus-neutralizing antibodies to vaccinia virus ≥1:40, at specified time intervals. — Groups 1, 2, 3: at days 0, 21, 30, 60, 90, 180. Group 4: at days 0, 5, 12, 21, 28, 37, 67, 97, 187.
- Recording the number of local reactions. — Groups 1, 2: at days 0 - 14, 21. Group 3: at days 0 - 14, 21, 28 - 42, 49. Group 4: at days 0 - 22, 29.
Цель исследования
The aim of the clinical study is to study the safety and tolerability of the live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus, in intracutaneous administration.
The research tasks are to:
* evaluate the safety of various schemes for the use of the VAC∆6 vaccine using a set of clinical and laboratory-instrumental methods (thermometry, blood pressure registration, auscultation of the heart and lungs, electrocardiography (ECG), complete blood count and common urine test, biochemical, immunological, and virological studies);
* evaluate the reactogenicity of various schemes for the use of the VAC∆6 vaccine (taking into account the number of local and systemic reactions, the percentage of those vaccinated with various degrees of manifestation of systemic and local reactions);
* evaluate the possibility of virus shedding into the environment by volunteers;
* evaluate the immunological efficacy of various vaccine administration schemes;
* identify the development of undesirable reactions to the administration of the vaccine;
* evaluate the cellular immune response to the introduction of various schemes for the use of the vaccine;
* evaluate preliminary efficacy data in order to select an optimal scheme for the administration of the vaccine to make a decision on conducting Phase II clinical trials in an extended group of volunteers.
Области и заболевания
Где проходит
1 центр в 1 городеОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 86 от 27.02.2019 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05762523 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
clinmarket · № 1256 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.